(Q41773434)

9 October 2017

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma (English)

1 reference

9 October 2017

1 reference

1

1 reference

9 October 2017

4

Jennifer A Wargo

1 reference

9 October 2017

Alexandre Reuben

2

1 reference

PMC publication ID

4292518

9 October 2017

Rodabe N Amaria

series ordinal

3

1 reference

9 October 2017

1 October 2014

1 reference

9 October 2017

1 reference

9 October 2017

3

1 reference

9 October 2017

9

1 reference

9 October 2017

e954956

1 reference

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

9 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Hepatotoxicity with combination of vemurafenib and ipilimumab

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292518

10.4161/21624011.2014.954956

6 June 2018

Identifiers

DOI

1 reference

9 October 2017

1 reference

PMC publication ID

4292518

9 October 2017

PubMed publication ID

25941608

1 reference

PMC publication ID

4292518